Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080422 | 0.90 | KDM4E (0.43) | PIM1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6597613 | 0.88 | ALOX15 (0.45) | PIM1GPR35KDM4EALOX15MEN1 | |
| SCHEMBL6080032 | 0.82 | KDM4E (0.41) | KDM4EALOX15L3MBTL1CYP2D6CYP2C19 | |
| SCHEMBL6080173 | 0.81 | KDM4E (0.44) | PIM1KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6081160 | 0.79 | PIM1 (0.38) | PIM1KDM4EALOX15MEN1KMT2A | |
| SCHEMBL6080655 | 0.79 | ALOX5 (0.50) | GPR35KDM4EALOX15GAA | |
| SCHEMBL6593629 | 0.77 | ALOX5 (0.49) | PIM1GPR35KDM4EALOX15GAA | |
| SCHEMBL6081075 | 0.74 | RNASEH1 (0.44) | — | |
| SCHEMBL6081017 | 0.72 | GPR35 (0.39) | GPR35KDM4EALDH1A1 | |
| SCHEMBL6081306 | 0.71 | PDE10A (0.45) | GPR35KDM4EALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | PIM1 3960/4885GPR35 1071/4885KDM4E 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.